Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Shares Issued (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Shares Issued for 4 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued fell 95.82% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Sep 2025, down 96.79%, and an annual FY2024 reading of $9.3 million, up 337.64% over the prior year.
  • Shares Issued was $1.5 million for Q3 2025 at Atara Biotherapeutics, up from $1000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $35.8 million in Q3 2024 and bottomed at -$19.1 million in Q3 2022.
  • Average Shares Issued over 4 years is $5.4 million, with a median of $640000.0 recorded in 2023.
  • Peak annual rise in Shares Issued hit 22902.55% in 2024, while the deepest fall reached 169.16% in 2024.
  • Year by year, Shares Issued stood at $20.4 million in 2022, then plummeted by 92.44% to $1.5 million in 2023, then skyrocketed by 2215.65% to $35.8 million in 2024, then plummeted by 95.82% to $1.5 million in 2025.
  • Business Quant data shows Shares Issued for ATRA at $1.5 million in Q3 2025, $1000.0 in Q2 2025, and $35.8 million in Q3 2024.